# Andrew Dervan

> Andrew Dervan is the Co-Founder and Co-CEO of Cajal Neuroscience (Cajal Therapeutics), a Seattle biotech that launched in 2022 with $96 million to rethink how drugs for Alzheimer's, Parkinson's, and other neurodegenerative diseases are discovered. A Harvard-trained physician with an MBA from Harvard Business School and a BA from Yale, he spent years leading cell therapy and immuno-oncology business development at Celgene and Bristol Myers Squibb. Unusually for a biotech CEO, he still sees patients as a practicing clinical geneticist at the University of Washington, evaluating people with adult-onset neurological conditions.

- **Role:** Co-Founder & Co-CEO at Cajal Neuroscience (Cajal Therapeutics)
- **Organizations:** Cajal Neuroscience / Cajal Therapeutics, University of Washington Medical Center, Life Science Washington, Celgene, Bristol Myers Squibb, 5AM Ventures
- **Nationality:** American
- **Education:** Bachelor of Arts, Yale University, Doctor of Medicine (MD), Harvard Medical School, Master of Business Administration (MBA), Harvard Business School, Residency in Internal Medicine; Fellowship in Medical Genetics, University of Washington
- **Known for:** Co-founded Cajal Neuroscience and helped raise a $96 million Series A in 2022, Led cell therapy and immuno-oncology business development at Celgene and Bristol Myers Squibb, Built and led a Translational Medicine team using single-cell sequencing for oncology target discovery

## Career timeline

- **Earlier** — Worked at Massachusetts General Hospital and venture firm 5AM Ventures
- **At Celgene** — Senior Director of Business Development, leading cell therapy partnerships and immuno-oncology transactions; led a Translational Medicine team applying single-cell sequencing to oncology target discovery
- **Bristol Myers Squibb** — Continued cell therapy business development following the BMS-Celgene combination
- **Ongoing** — Practicing clinical geneticist at the University of Washington Medical Center, evaluating patients with genetic conditions including adult-onset neurological disease
- **2022** — Co-founded Cajal Neuroscience and helped launch it with $96M Series A led by The Column Group and Lux Capital; initially Chief Operating Officer, later Co-CEO

## Achievements

- Co-founded Cajal Neuroscience and helped raise a $96 million Series A in 2022
- Led cell therapy and immuno-oncology business development at Celgene and Bristol Myers Squibb
- Built and led a Translational Medicine team using single-cell sequencing for oncology target discovery
- Maintains an active clinical practice in medical genetics at the University of Washington while running a biotech
- Serves on the board / executive committee of Life Science Washington

## Latest updates

- **2022-11** — Cajal Neuroscience launched publicly with $96M Series A financing led by The Column Group and Lux Capital.

## Links

- Website: https://cajal-tx.com
- LinkedIn: http://www.linkedin.com/in/andrewdervan

---

Profile page: https://yespress.io/andrew-dervan
Published by YesPress — https://yespress.io
Last updated: 2026-06-14